Brief: Clearside Biomedical Announces Plans For Phase 2B Trial Of Cls-Ax In Wet AMD
18/04/2023 12:13
April 18 (Reuters) - Clearside Biomedical Inc CLSD.O :
* CLEARSIDE BIOMEDICAL ANNOUNCES PLANS FOR ODYSSEY PHASE 2B
CLINICAL TRIAL OF CLS-AX (AXITINIB INJECTABLE SUSPENSION) IN WET
AMD
* CLEARSIDE BIOMEDICAL INC - ODYSSEY TOPLINE RESULTS
EXPECTED IN
Q3 2024
* CLEARSIDE BIOMEDICAL INC - MULTIPLE U.S. CLINICAL SITES TO
BEGIN
ENROLLING ODYSSEY PARTICIPANTS THIS QUARTER
Source text for Eikon: ID:nGNX9jMJDt
Further company coverage: CLSD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearside Biomedical,
See all newsBrief: Clearside Biomedical Completes Financial Restructuring And Emerges From Chapter 11 With Steel Partners As Plan Sponsor
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Clearside Biomedical plunges after filing for Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials